« Return to News | Awards & Advancement

Sidra Medical appoints William F. Owen Jr. as CEO

Thursday, July 26, 2012 04:18 PM

American healthcare leader Dr. William F. Owen, Jr., M.D., FACP, has been appointed CEO of Sidra Medical and Research Center, a Qatar-based medical, research and education institution that focuses on the health and well-being of women and children, effective August 5, 2012.

Owen's most recent executive role was president of the University of Medicine and Dentistry of New Jersey (UMDNJ), America's largest, publicly funded academic health system. As a seasoned academic health system leader, he has substantive experience building and managing international health and educational services in several of America's elite universities.

Owen will be responsible for the strategic direction of all clinical and operational services of the Sidra Medical and Research Center and lead Sidra to deliver the highest standard of patient care. Reporting directly to the Sidra’s board of governors, his first responsibility will be planning, commissioning and launching the state-of-the-art Sidra facility in line with its vision and targets. Owen will also be responsible for further recruitment and leadership of the executive team at Sidra.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.